James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Urol. 2021 Apr;205(4):1069-1074. doi: 10.1097/JU.0000000000001523. Epub 2020 Dec 1.
Transperineal prostate biopsy offers improved sampling of the anterior prostate compared to the transrectal approach. The objective of this study was to determine if transperineal prostate biopsy is associated with an increased incidence of cancer upgrading among men on active surveillance for very low or low risk prostate cancer.
Our active surveillance registry was queried to identify patients who underwent a surveillance biopsy following the introduction of transperineal prostate biopsy at our institution. Patients were dichotomized by the type of biopsy performed. The baseline characteristics and rates of cancer upgrading were compared between groups.
Between November 2017 and June 2020, 790 men with very low or low risk prostate cancer underwent a surveillance biopsy. In total, 59 of 279 men (21.2%) in the transperineal prostate biopsy group were upgraded to grade group ≥2 as compared to 75 of 511 (14.7%) in the transrectal biopsy group (p=0.01). Among patients who were upgraded to grade group ≥2, 26 of 59 (44%) had grade group ≥2 detected in the anterior/transition zone with transperineal prostate biopsy compared to 14 of 75 (18.7%) with transrectal biopsy (p=0.01). Additionally, 17 of 279 men (6.1%) who underwent transperineal prostate biopsy were upgraded to grade group ≥3 vs 17 of 511 (3.3%) who underwent transrectal biopsy (p=0.05). After adjusting for age, prostate specific antigen density, use of magnetic resonance imaging, and number of prior transrectal biopsies, transperineal prostate biopsy was significantly associated with upgrading to grade group ≥2 (OR 1.49, 95% CI 1.11-2.19, p=0.01).
Among men on active surveillance for very low or low risk prostate cancer, transperineal prostate biopsy was associated with an increased likelihood of upgrading to clinically significant prostate cancer. This is likely due to improved sampling of the anterior prostate with the transperineal approach.
与经直肠方法相比,经会阴前列腺活检可提高对前列腺前部的采样。本研究的目的是确定经会阴前列腺活检是否与接受非常低或低危前列腺癌主动监测的男性中癌症升级的发生率增加有关。
我们的主动监测登记处被查询,以确定在我们的机构引入经会阴前列腺活检后接受监测活检的患者。患者按进行的活检类型分为两类。比较两组之间的基线特征和癌症升级率。
在 2017 年 11 月至 2020 年 6 月期间,790 名患有非常低或低危前列腺癌的男性接受了监测活检。在经会阴前列腺活检组中,共有 279 名男性中的 59 名(21.2%)升级为≥2 级分组,而在经直肠活检组中,511 名男性中有 75 名(14.7%)升级为≥2 级分组(p=0.01)。在升级为≥2 级分组的患者中,经会阴前列腺活检检测到的前/移行区≥2 级的有 59 名中的 26 名(44%),而经直肠活检的有 75 名中的 14 名(18.7%)(p=0.01)。此外,279 名接受经会阴前列腺活检的男性中有 17 名(6.1%)升级为≥3 级,而 511 名接受经直肠活检的男性中有 17 名(3.3%)升级为≥3 级(p=0.05)。在调整年龄、前列腺特异性抗原密度、磁共振成像的使用和先前经直肠活检的数量后,经会阴前列腺活检与升级为≥2 级显著相关(OR 1.49,95%CI 1.11-2.19,p=0.01)。
在接受非常低或低危前列腺癌主动监测的男性中,经会阴前列腺活检与升级为具有临床意义的前列腺癌的可能性增加相关。这可能是由于经会阴方法提高了对前列腺前部的采样。